4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
203 406 3700
|Mr. Christopher A. Posner||Pres, CEO & Director||1,2M||N/A||1970|
|Mr. Ryan D. Maynard||Chief Financial Officer||511,7k||N/A||1969|
|Dr. Joana Goncalves M.D.||Chief Medical Officer||747,25k||N/A||1974|
|Dr. Derek T. Chalmers D.Sc., Ph.D.||Co-Founder & Sr. Advisor||N/A||N/A||1964|
|Dr. Frédérique Menzaghi||Chief Scientific Officer and Sr. VP of R&D||N/A||N/A||1966|
|Dr. Iris Francesconi Ph.D.||Chief Strategy Officer & Head of Investor Relations||N/A||N/A||N/A|
|Mr. Scott M. Terrillion||Chief Compliance Officer, Gen. Counsel & Corp. Sec.||N/A||N/A||1963|
|Mr. Eric Vandal||Sr. VP of Commercial||N/A||N/A||N/A|
|Ms. Beth Weinberg R.Ph.||Sr. VP of Regulatory Affairs & QA||N/A||N/A||N/A|
|Mr. Matthew Murphy||Mang. of Investor Relations||N/A||N/A||N/A|
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
Cara Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2023, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 7, Kompensation: 8.